Crystalvue Medical Co Ltd

Crystalvue Medical Co Ltd

TTPEX:6527
71.50
TWD
-0.50
(-0.69%)
5.96EPS
12.39P/E
1.90BMarket Cap
Mar 24Next Earn

Total Valuation

TWD

As of September 30, 2026, Crystalvue Medical Co Ltd carries a market capitalization of 1.90B, placing it among publicly traded companies globally. Its enterprise value stands at 1.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.90B
Enterprise Value1.89B

Important Dates

Crystalvue Medical Co Ltd's next confirmed earnings release is scheduled for March 24, 2027.

Earnings Date3/24/2027

Share Statistics

As of September 30, 2026, Crystalvue Medical Co Ltd has 25.34M shares outstanding.

Shares Outstanding25.34M

Valuation Ratios

As of September 30, 2026, Crystalvue Medical Co Ltd trades at a trailing price-to-earnings ratio of 12.39. The price-to-sales ratio is 2.13, and the price-to-book ratio stands at 1.77.

PE Ratio12.39
PS Ratio2.13
PB Ratio1.77
P/TBV Ratio1.78
P/FCF Ratio-955.06
P/OCF Ratio12.84

Enterprise Valuation

As of September 30, 2026, Crystalvue Medical Co Ltd trades at an EV/EBITDA multiple of 9.78 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.47 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.89B versus a market cap of 1.90B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.12
EV / EBITDA9.78
EV / EBIT10.47

Financial Position

As of September 30, 2026, Crystalvue Medical Co Ltd maintains a current ratio of 2.63, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.01, indicating elevated leverage, while an interest coverage ratio of 658.07 demonstrates strong ability to service its debt obligations.

Current Ratio2.63
Quick Ratio0.48
Debt / Equity9.01
Debt / EBITDA0.50
Interest Coverage658.07

Financial Efficiency

TWD

These figures cover the twelve months ended September 30, 2026. The company generates approximately 8.28M in revenue per employee across its workforce of 108.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee8.28M
Employee Count108.00

Taxes

TWD

Over the twelve months ended September 30, 2026, Crystalvue Medical Co Ltd recorded 36.23M in income tax expense. That works out to an effective tax rate of 19.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 189.65M, leaving 153.42M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax36.23M
Effective Tax Rate19.10

Stock Price Statistics

TWD

As of the close on November 17, 2026, Crystalvue Medical Co Ltd's stock has declined approximately 12.27% over the past 52 weeks. The 50-day moving average sits at 73.65, while the 200-day moving average is 72.74.

52-Week Price Change-12.27%
50-Day Moving Average73.65
200-Day Moving Average72.74

Income Statement

TWD

Over the twelve months ended September 30, 2026, Crystalvue Medical Co Ltd generated 894.60M in revenue and converted that into 153.42M in net income, yielding earnings per share of 5.96. EBITDA reached 193.47M, while operating income came in at 180.84M.

Revenue894.60M
Gross Profit345.79M
Operating Income180.84M
Pretax Income189.65M
Net Income153.42M
EBITDA193.47M
EBIT180.84M
Earnings Per Share (EPS)5.96

Balance Sheet

TWD

As of September 30, 2026, Crystalvue Medical Co Ltd holds 104.36M in cash and equivalents against 96.51M in total debt, resulting in a net debt position of -14.36M. Total book value stands at 1.07B, with working capital of 358.59M providing operational flexibility.

Cash & Cash Equivalents104.36M
Total Debt96.51M
Net Debt-14.36M
Equity (Book Value)1.07B
Book Value Per Share42.26
Working Capital358.59M

Cash Flow

TWD

Crystalvue Medical Co Ltd produced 148.11M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -150.13M in capital expenditures, free cash flow totaled -2.02M - equivalent to -0.08 per share.

Operating Cash Flow148.11M
Capital Expenditures-150.13M
Free Cash Flow-2.02M
FCF Per Share-0.08

Margins

Over the twelve months ended September 30, 2026, Crystalvue Medical Co Ltd posted a gross margin of 38.65, reflecting its pricing power and cost economics. The operating margin of 20.21 and net profit margin of 17.15 provide insight into operational efficiency.

Gross Margin38.65
Operating Margin20.21
Pretax Margin21.20
Profit Margin17.15
EBITDA Margin21.63

Dividends & Yields

Over the twelve months ended September 30, 2026, Crystalvue Medical Co Ltd paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.51, meaning Crystalvue Medical Co Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.51
FCF Yield-0.10

Stock Splits

Crystalvue Medical Co Ltd's most recent stock split took place on July 25, 2023 with a 20:21 split ratio.

Last Split Date7/25/2023
Split Ratio20:21

Scores

As of September 30, 2026, Crystalvue Medical Co Ltd has an Altman Z-Score of 5.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.58